Pegylated interferon, ribavirin, and frequent supportive therapy with growth factors. Which pathogenesis for a severe psoriasis complicating the treatment of chronic HCV hepatitis?
DOI:
https://doi.org/10.7175/cmi.v3i4.542Keywords:
Chronic HCV infection, Peginterferon, Ribavirin, Filgrastim, Adverse events, Psoriasis, CyclosporinAbstract
One of the most effective treatments for HCV and HBV infection is the combination of pegylated IFN-alpha and ribavirin. However, both IFN-alpha and ribavirin can induce hematologic toxicity, which can compromise treatment adherence and dose maintenance and could, therefore, influence outcomes. Hematopoietic growth factors (e.g. filgrastim) can provide significant benefits in the treatment of this toxicity, but they can also exacerbate cutaneous psoriasis. We report a case of a 54-year-old woman with chronic, progressive hepatitis C, treated with long-term pegylated interferon plus ribavirin, associated with multiple cycles of filgrastim for a severe, recurring granulocytopenia. The patient developed an extensive and severe psoriasis, which improved only after specific treatment with cyclosporin. The case highlights the importance of treatment adherence and dose maintenance to obtain a sustained virologic response, and underlines the difficulties of the management of this disease when side effects, such as hematologic toxicity and psoriasis, are present.Downloads
Published
2009-12-15
Issue
Section
Case report
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)